Historically, small molecule drugs have been precisely designed down to the atomic scale. Considering their relatively large complex structures, nanomedicines have lagged behind. Researchers argue ...

The technology is genuinely useful for scientific discovery, but its applications are less dramatic than you might think.

Historically, the vast majority of pharmaceutical drugs have been meticulously designed down to the atomic level. The ...

A scientific revolution is underway as researchers push to bring atomic-level precision, once reserved for small molecule ...

While artificial intelligence (AI) has shown promising potential, much of its use has remained theoretical or retrospective.

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and ...

Press Release Grove Biopharma, a private biotechnology company pioneering its Bionic Biologics™ platform to develop therapies targeting previously intractable intracellular disease targets, today ...

Hassabis also spoke to Reid Hoffman, co-founder of LinkedIn, about the scale and speed at which AI is transforming science. Using DeepMind’s AlphaFold technology, researchers managed to predict the ...

GenAI offers a realistic path forward in tackling previously undruggable targets, with the potential to reshape the entire ...

Google DeepMind CEO Demis Hassabis envisions AI eradicating all diseases within a decade, potentially revolutionizing drug ...

With the Trump administration making sweeping cuts to staff and research grants at science-related agencies, artificial ...

Exscientia, headquartered in Oxford, UK, has been a pioneer in integrating AI into small-molecule drug design. The company’s platform, Centaur Chemist, combines human expertise with AI to generate ...